804 related articles for article (PubMed ID: 35928454)
21. A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer.
Wang L; Xiao K; Dong Z; Meng T; Cheng X; Xu Y
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10543-10559. PubMed ID: 37291405
[TBL] [Abstract][Full Text] [Related]
22. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma.
Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; Abrão FC; Puthamohan VM; Liu L; Jiang T
Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454
[TBL] [Abstract][Full Text] [Related]
23. A pyroptosis-related lncRNA signature predicts prognosis and immune microenvironment in head and neck squamous cell carcinoma.
Zhu W; Ye Z; Chen L; Liang H; Cai Q
Int Immunopharmacol; 2021 Dec; 101(Pt B):108268. PubMed ID: 34688154
[TBL] [Abstract][Full Text] [Related]
24. Pyroptosis-Related lncRNA Prognostic Model for Renal Cancer Contributes to Immunodiagnosis and Immunotherapy.
Zhou X; Yao L; Zhou X; Cong R; Luan J; Wei X; Zhang X; Song N
Front Oncol; 2022; 12():837155. PubMed ID: 35860590
[TBL] [Abstract][Full Text] [Related]
25. Development and Validation of Lactate Metabolism-Related lncRNA Signature as a Prognostic Model for Lung Adenocarcinoma.
Mai S; Liang L; Mai G; Liu X; Diao D; Cai R; Liu L
Front Endocrinol (Lausanne); 2022; 13():829175. PubMed ID: 35422758
[TBL] [Abstract][Full Text] [Related]
26. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
27. A novel pyroptosis-related prognostic signature for lung adenocarcinoma: Identification and multi-angle verification.
Wang X; Zhou J; Li Z; Chen X; Wei Q; Chen K; Jiang R
Front Genet; 2023; 14():1160915. PubMed ID: 37077542
[No Abstract] [Full Text] [Related]
28. Competitive endogenous RNA network identifies four long non-coding RNA signature as a candidate prognostic biomarker for lung adenocarcinoma.
Hu J; Wang T; Chen Q
Transl Cancer Res; 2019 Aug; 8(4):1046-1064. PubMed ID: 35116848
[TBL] [Abstract][Full Text] [Related]
29. Identification and Validation of a Novel Necroptosis-Related Long Noncoding RNA Prognostic Signature for Lung Adenocarcinoma.
Zeng C; Yu H; Liu X; Liu Q; Jin J
Biomed Res Int; 2022; 2022():9710540. PubMed ID: 36330457
[TBL] [Abstract][Full Text] [Related]
30. Identification of a RNA-Seq Based Prognostic Signature with Seven Immune-Related lncRNAs for Lung Adenocarcinoma.
You J; Fang W; Zhao Q; Chen L; Chen L; Chen F
Clin Lab; 2021 Mar; 67(3):. PubMed ID: 33739047
[TBL] [Abstract][Full Text] [Related]
31. A Novel Pyroptosis-Associated Long Non-coding RNA Signature Predicts Prognosis and Tumor Immune Microenvironment of Patients With Breast Cancer.
Ping L; Zhang K; Ou X; Qiu X; Xiao X
Front Cell Dev Biol; 2021; 9():727183. PubMed ID: 34616734
[No Abstract] [Full Text] [Related]
32. Development of a Novel Pyroptosis-Associated lncRNA Biomarker Signature in Lung Adenocarcinoma.
Wang P; Wang Z; Lin Y; Castellano L; Stebbing J; Zhu L; Peng L
Mol Biotechnol; 2024 Feb; 66(2):332-353. PubMed ID: 37154865
[TBL] [Abstract][Full Text] [Related]
33. Cross-talk between necroptosis-related lncRNAs to construct a novel signature and predict the immune landscape of lung adenocarcinoma patients.
Wu J; Song D; Zhao G; Chen S; Ren H; Zhang B
Front Genet; 2022; 13():966896. PubMed ID: 36186456
[No Abstract] [Full Text] [Related]
34. Prognostic model and immunotherapy prediction based on molecular chaperone-related lncRNAs in lung adenocarcinoma.
Xu Y; Tao T; Li S; Tan S; Liu H; Zhu X
Front Genet; 2022; 13():975905. PubMed ID: 36313456
[No Abstract] [Full Text] [Related]
35. Pyroptosis-Related LncRNA Signature Predicts Prognosis and Is Associated With Immune Infiltration in Hepatocellular Carcinoma.
Liu ZK; Wu KF; Zhang RY; Kong LM; Shang RZ; Lv JJ; Li C; Lu M; Yong YL; Zhang C; Zheng NS; Li YH; Chen ZN; Bian H; Wei D
Front Oncol; 2022; 12():794034. PubMed ID: 35311105
[TBL] [Abstract][Full Text] [Related]
36. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
37. A novel pyroptosis-related lncRNA prognostic signature associated with the immune microenvironment in lung squamous cell carcinoma.
Zhou W; Zhang W
BMC Cancer; 2022 Jun; 22(1):694. PubMed ID: 35739504
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Value of Genomic Instability of m
Li R; Li JP; Liu TT; Huo C; Yao J; Ji XL; Qu YQ
Front Cell Dev Biol; 2022; 10():707405. PubMed ID: 35309906
[No Abstract] [Full Text] [Related]
39. Prognostic significance of pyroptosis-related factors in lung adenocarcinoma.
Lin X; Zhou T; Hu S; Yang L; Yang Z; Pang H; Zhou X; Zhong R; Fang X; Yu Z; Hu K
J Thorac Dis; 2022 Mar; 14(3):654-667. PubMed ID: 35399245
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.
Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y
Front Immunol; 2022; 13():950001. PubMed ID: 36091041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
